AstraZeneca’s dual-targeting CAR-T AZD0120 shows similar response rates in Western and Chinese patients

AZD0120 (also known as GC012F) is AstraZeneca’s dual‑targeting CAR‑T therapy directed against CD19 and BCMA, being developed for multiple myeloma and other indications.24

The product originated as GC012F in China, where early-phase studies in relapsed/refractory multiple myeloma reported very high response rates (around mid‑90% overall response) in heavily pretreated patients.15

At ASH, AstraZeneca reported data from the DURGA‑1 trial in heavily pretreated multiple myeloma showing an overall response rate of about 96% with AZD0120 in largely Western trial populations.5

These DURGA‑1 results indicate that response rates in Western patients are broadly similar to those previously reported in Chinese studies of GC012F, suggesting the dual‑targeting design maintains efficacy across populations.15

Ongoing and planned Phase I/II trials (e.g., D8310C00001 and NCT07073547) are expanding evaluation of AZD0120 in relapsed/refractory and earlier-line multiple myeloma in multinational settings, to confirm safety, durability of response, and cross‑regional consistency of outcomes.24

Across studies, the safety profile is described as manageable and consistent with CAR‑T expectations, with monitored risks including cytokine release syndrome and infections, which are being characterized further in larger cohorts.14

Sources:

1. https://library.ehaweb.org/eha/2025/eha2025-congress/4160786/juan.du.updated.results.of.a.phase.i.open-label.single-arm.study.of.dual.html?f=

2. https://www.astrazenecaclinicaltrials.com/study/D8310C00001

4. https://www.clinicaltrials.gov/study/NCT07073547

5. https://pharmaphorum.com/news/ash-astrazenecas-dual-wielding-car-t-shows-promise